Stockscreener 앱 받기
0.1001
5.89%
0.0051
전일 마감가:
$0.095
열려 있는:
$0.1102
하루 거래량:
49.09M
Relative Volume:
1.38
시가총액:
$13.93M
수익:
-
순이익/손실:
$-27.39M
주가수익비율:
-0.0596
EPS:
-1.6803
순현금흐름:
$-2.09M
1주 성능:
+10.55%
1개월 성능:
-5.36%
6개월 성능:
-72.48%
1년 성능:
+0.00%
1일 변동 폭
$0.0971
$0.1102
1주일 범위
$0.0709
$0.1144
52주 변동 폭
$0.0709
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
명칭
Aspire Biopharma Holdings Inc
전화
561-704-8527
주소
23150 FASHION DRIVE, SUITE 232, ESTERO
ASBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.1006 | 13.15M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.56 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.11 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
840.60 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.82 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
199.15 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스
Aspire Biopharma Provides Q3 2025 Business Update - The Florida Times-Union
Aspire Biopharma Holdings (ASBP) Stock on Dec. 15, 2025: Nasdaq Extension, FDA Pre‑IND Momentum, and Dilution Risks Investors Are Watching - ts2.tech
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Peoria Journal Star
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance With Continued Listing Requirements - 富途牛牛
Aspire Biopharma gets Nasdaq extension to meet listing requirements By Investing.com - Investing.com Nigeria
Aspire Biopharma gets Nasdaq extension to meet listing requirements - Investing.com
POWP ACQUPAR : Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - marketscreener.com
Aspire Biopharma (Nasdaq: ASBP) gains extension, moves to Nasdaq Capital Market - Stock Titan
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Pensacola News Journal
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Victorville Daily Press
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Alliance Review
Aspire Biopharma advances sublingual drug delivery technology By Investing.com - Investing.com Nigeria
Aspire Biopharma advances sublingual drug delivery technology - Investing.com
Aspire Biopharma (Nasdaq: ASBP) targets H1 2026 NDA after fast-acting aspirin data - Stock Titan
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Montgomery Advertiser
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aspire Biopharma (NASDAQ: ASBP) Requests FDA Pre-IND Meeting on Sublingual AMI Aspirin - Stock Titan
Aspire Biopharma Holdings Inc (ASBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.56%
1.23%
자본화:
|
볼륨(24시간):